Charles River Laboratories (NYSE:CRL)
| CAPS Rating |
|
|---|---|
| Open | $34.51 |
| Previous Close | $34.81 |
| Daily Range | $33.67 - $34.57 |
| 52-Week Range | $25.52 - $42.84 |
| Market Cap | $1.73B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 273,566 |
| Average Daily Volume | 0 |
CRL
VS S&P 500 (SPY)
How do you think CRL will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CRL Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CRL News and Commentary
- Update on VPHM's Industrial Facility - Analyst Blog – NASDAQ
- Novo Nordisk Posts Solid 4Q - Analyst Blog – NASDAQ
- Why Charles River Laboratories International May Be About to Take Off – The Motley Fool
- Why Drug Development Company Charles River Laboratories Is Undervalued – Minyanville
- MannKind Treads the Neutral Path - Analyst Blog – NASDAQ
- Bristol-Myers/AstraZeneca get CRL - Analyst Blog – NASDAQ
- Company News for January 11, 2012 - Corporate Summary – NASDAQ
- Charles River Shares Soared: What You Need to Know – The Motley Fool
- Arena Pharma Files Response to CRL - Analyst Blog – NASDAQ
- Charles River Guides Higher - Analyst Blog – NASDAQ
- Don't Get Too Worked Up Over ICON's Earnings – The Motley Fool
- Good News for Endo Pharma - Analyst Blog – NASDAQ
- Risk-Reward Balanced at Theravance - Analyst Blog – NASDAQ
- Smart Money Picks: Biotech Stocks With Bullish Short Trends – The Motley Fool
- PPDI Shareholders Nod to Merger - Analyst Blog – NASDAQ
- MannKind in Neutral Lane - Analyst Blog – NASDAQ
- Are Shorts Watching Pharmaceutical Product Development? – The Motley Fool
- Whoa! My Stock Just Whomped the Market! – The Motley Fool
- 1 Special Stock Pick From an Outside View – The Motley Fool
- Here's How Covance Is Making You So Much Cash – The Motley Fool
RSS Headlines
Fool UK
